What is CSA BioTech?
CSA BioTech is a clinical-stage biotechnology company focused on Epidermolysis Bullosa and innate immune system-inspired science.
Quick Answers
Frequently Asked Questions
Direct answers about CSA BioTech's company focus, science platform, and investigational CAV-121 development program.
What is CAV-121?
CAV-121 is an investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa.
What are ceragenins?
Ceragenins are synthetic small molecules designed to mimic key properties of antimicrobial peptides such as cathelicidins.
What are cathelicidins?
Cathelicidins are antimicrobial peptides involved in innate immune defense, microbial control, immune modulation, and wound-healing biology.
Is CAV-121 FDA-approved?
No. CAV-121 is investigational and has not been approved by the FDA or any other regulatory authority. Its safety and efficacy have not been established.
What condition is CSA BioTech focused on?
CSA BioTech is focused on Epidermolysis Bullosa, a rare genetic skin-fragility disease associated with blistering, chronic wounds, pain, and infection risk.